Notable Monday Option Activity: POWL, CYTK, FUBO

Cytokinetics (CYTK) and FuboTV (FUBO) are seeing unusually large options activity: CYTK options volume is 11,482 contracts (~1.1M underlying shares), about 51.5% of its one‑month average daily volume, led by 5,012 contracts in the $70 May 15, 2026 call (~501,200 shares). FUBO options volume is 51,955 contracts (~5.2M underlying shares), about 50.5% of its one‑month average daily volume, led by 28,711 contracts in the $2.50 Jan 16, 2026 put (~2.9M shares). Such concentrated flows can reflect large directional bets or hedges and are likely to influence intraday liquidity and volatility in both names.

Analysis

Contrarian angles: The market may be mistaking large put volume for fresh conviction—28k+ FUBO puts could be portfolio insurance; if FUBO falls >40% within 2–4 weeks on flow alone, be prepared to buy cheap OTM call spreads (e.g., 3–6 month $2/$5) for mean reversion. For CYTK, heavy call buying can create a stretched long gamma environment; if CYTK fails to breach $70 by March 2026, cut exposure—the market may have front‑loaded optimism. Historical parallels: concentrated options flow often precedes short-term squeezes but reverses after catalysts; manage size and prefer defined-risk structures.

Key Decisions for Investors

• Establish a 1–2% portfolio long in CYTK via a May 15, 2026 $60/$80 call debit spread to capture upside implied by heavy $70 call flow while capping max loss to premium; scale in over 7 trading days to average cost.
• Establish a 1–2% portfolio bearish position in FUBO by buying Jan 16, 2026 $2.50 puts (or a $5/$2.50 put spread) OR short up to 1% of float-equivalent equity with a strict 15% stop—prioritize defined-risk options if funding is constrained.
• Implement a relative-value pair: long CYTK call-spread (size 1%) funded by shorting 0.5–1% exposure to a small-cap biotech ETF or basket to isolate CYTK-specific upside risk, review after any clinical or partner announcements within 90 days.
• If implied volatility for either name exceeds its 30-day average by >30% post-catalyst, sell premium via iron-condors or calendars (size ≤0.5% portfolio) to monetize mean reversion in IV; avoid naked short options.